Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cinacalcet hydrochloride (Amgen).

Jameel Iqbal¹, Mone Zaidi, Adina E Schneider

¹Mount Sinai Bone Program, Division of Endocrinology, Mount Sinai School of Medicine, New York, NY 10029, USA.

Idrugs : the Investigational Drugs Journal

|June 18, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> Mutation.

bioRxiv : the preprint server for biology·2026

Same author

From discovery to therapeutic development of monoclonal antibodies.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Erythroferrone Modulates Osteoblast-Osteoclast Crosstalk During Bone Remodeling.

bioRxiv : the preprint server for biology·2026

Same author

Neuroendocrine and neural control of bone mass in health and disease.

The Journal of clinical investigation·2026

Same author

Erythroferrone derived from osteoblasts regulates stress erythropoiesis.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Atlas of GLP-1 expression in the mouse brain: Neuroanatomical basis for metabolic and psychiatric effects.

Brain medicine : from neurons to behavior and better health·2026

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Cinacalcet hydrochloride, a calcimimetic, is being developed to treat hyperparathyroidism. It aims to improve upon the pharmacokinetic and metabolic limitations of the earlier compound, tecalcet hydrochloride.

Area of Science:

Pharmacology
Drug Development
Endocrinology

Background:

Primary and secondary hyperparathyroidism are significant health concerns.
Calcimimetics represent a class of drugs targeting parathyroid hormone secretion.
Tecalcet hydrochloride was an early calcimimetic with studied pharmacological data.

Purpose of the Study:

To introduce cinacalcet hydrochloride, a novel calcimimetic.
To address the limitations of tecalcet hydrochloride's pharmacokinetics and metabolism.
To explore cinacalcet hydrochloride's potential in treating hyperparathyroidism.

Main Methods:

Development of cinacalcet hydrochloride by Amgen and Kirin Brewery.
Licensing agreement with NPS Pharmaceuticals Inc.

Related Experiment Videos

Pharmacological investigation of calcimimetic compounds.

Main Results:

Cinacalcet hydrochloride is the lead compound in its class.
Development focused on overcoming tecalcet hydrochloride's pharmacokinetic issues.
Data suggests potential for improved drug performance.

Conclusions:

Cinacalcet hydrochloride shows promise for treating hyperparathyroidism.
The compound offers potential advantages over earlier calcimimetics.
Further research is warranted to fully elucidate its therapeutic benefits.